BETting on the future: BET inhibition for patients with lymphoma.
Despite available treatments, patients with lymphoma may still develop relapsed or refractory diseases, highlighting the need for new therapies. Zhang et al.1 report a phase I dose-escalation study of TQB3617, a novel BET inhibitor, in diverse lymphoma subtypes. The study showed promising safety and efficacy, including T cell and Hodgkin lymphoma, warranting further investigation.